IRIS
IZZO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.483
AS - Asia 2.042
NA - Nord America 1.937
SA - Sud America 894
AF - Africa 64
OC - Oceania 4
Totale 7.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.706
SG - Singapore 1.170
IT - Italia 908
RU - Federazione Russa 846
BR - Brasile 666
CN - Cina 438
MX - Messico 157
HK - Hong Kong 146
VN - Vietnam 144
UA - Ucraina 142
DE - Germania 133
NL - Olanda 113
FI - Finlandia 84
CO - Colombia 60
GB - Regno Unito 57
CA - Canada 48
EC - Ecuador 46
FR - Francia 44
IE - Irlanda 38
AR - Argentina 35
ES - Italia 29
IN - India 29
PE - Perù 28
BO - Bolivia 23
ZA - Sudafrica 23
KR - Corea 21
BD - Bangladesh 19
CL - Cile 19
CI - Costa d'Avorio 17
SE - Svezia 17
JP - Giappone 13
AT - Austria 11
PL - Polonia 11
CH - Svizzera 10
ID - Indonesia 10
VE - Venezuela 9
TR - Turchia 8
HN - Honduras 6
IQ - Iraq 6
ET - Etiopia 5
LV - Lettonia 5
MY - Malesia 5
PT - Portogallo 5
BE - Belgio 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
HR - Croazia 4
KE - Kenya 4
MA - Marocco 4
PY - Paraguay 4
UZ - Uzbekistan 4
BG - Bulgaria 3
GE - Georgia 3
IR - Iran 3
LT - Lituania 3
PK - Pakistan 3
RO - Romania 3
SA - Arabia Saudita 3
TH - Thailandia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
BW - Botswana 2
CU - Cuba 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EG - Egitto 2
LB - Libano 2
LU - Lussemburgo 2
PA - Panama 2
SN - Senegal 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
IL - Israele 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
ML - Mali 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
RS - Serbia 1
SO - Somalia 1
SV - El Salvador 1
Totale 7.421
Salva come PNG Salva come JPEG
Città #
Singapore 517
Moscow 229
Chandler 176
Ashburn 158
Beijing 152
Hong Kong 146
Amsterdam 101
Naples 96
Hefei 91
Napoli 80
Jacksonville 68
Santa Clara 63
Los Angeles 59
Ho Chi Minh City 53
Millbury 52
Rome 52
Munich 51
Princeton 44
São Paulo 42
Boston 37
Milan 36
New York 30
Buffalo 29
Nanjing 28
Turku 25
Des Moines 24
Lima 23
Ottawa 23
Quito 23
Hanoi 21
Medellín 21
Mexico 21
Redondo Beach 21
Woodbridge 20
Wilmington 18
Brasília 17
La Paz 17
Seoul 17
Poplar 16
Santiago 15
Seattle 15
Bogotá 14
Dallas 13
Dong Ket 12
Helsinki 12
Shenyang 12
Bari 11
Brooklyn 11
Cuenca 11
Denver 11
Falls Church 11
Salvador 11
Tokyo 11
Warsaw 11
Chicago 10
Houston 10
Johannesburg 10
Lawrence 10
Salerno 10
San Jose 10
Caserta 9
Fortaleza 9
London 9
Mexico City 9
Montreal 9
Belo Horizonte 8
Chennai 8
Haiphong 8
Hebei 8
Nanchang 8
Nuremberg 8
The Dalles 8
Atlanta 7
Buenos Aires 7
Florence 7
Frankfurt am Main 7
Genova 7
Manaus 7
Orem 7
Rio de Janeiro 7
Tijuana 7
Toronto 7
Bologna 6
Council Bluffs 6
Kronberg 6
Monterrey 6
Palmi 6
Veracruz 6
Vienna 6
Ankara 5
Brescia 5
Campo Grande 5
Canoas 5
Curitiba 5
Guadalajara 5
Guarujá 5
Lappeenranta 5
Mendoza 5
Mumbai 5
New Delhi 5
Totale 3.206
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.402
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 385
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 173
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 140
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 137
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 136
Laboratory medicine: health evaluation in elite athletes 133
Spleen is the dark side of essential Thrombocitemia 126
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 124
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 121
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 121
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 120
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 119
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 116
Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry 114
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 113
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 113
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 111
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 111
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 110
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 110
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition 108
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 108
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 107
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 107
MiR‐27a downregulates 14‐3‐3θ, RUNX1, AF4, and MLL‐AF4, crucial drivers of blast transformation in t(4;11) leukemia cells 106
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 106
Molecular Analysis of Cluster Headache 105
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 103
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 101
SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods 101
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 96
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 95
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche 93
Molecular monitoring in chronic myeloid leukemia (CML) 91
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study 89
c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche 89
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 88
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 87
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 86
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 84
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study 83
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 81
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 81
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 80
Droplet digital pcr for bcr–abl1 monitoring in diagnostic routine: Ready to start? 79
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 74
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. 74
Wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes 73
Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary review 69
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 69
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 69
Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe 68
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 67
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 62
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 62
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 58
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 58
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale 58
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy 56
Late appearance of t(8;14) with c-myc rearrangement and disappearance of JH rearrangement leading to aggressive progression in a case of low grade non Hodgkin’s lymphoma” 52
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 51
Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia 40
Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical bcr-abl1 transcripts 38
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype 37
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches 24
Totale 7.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.001
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.001
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021140 0 0 0 0 0 35 25 4 24 16 19 17
2021/2022444 33 4 6 6 6 17 21 17 51 28 140 115
2022/2023497 58 29 19 17 57 53 3 57 71 92 32 9
2023/2024361 17 50 71 17 22 52 12 41 8 9 45 17
2024/20251.931 94 97 15 58 57 81 195 111 167 187 712 157
2025/20262.212 386 282 388 386 634 136 0 0 0 0 0 0
Totale 7.648